Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
denfivontinib
- Development stage
- Phase 1
- Lead developer
- XOMA
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Denfivontinib is a small molecule, oral multi-kinase inhibitor developed for the treatment of various solid tumors. It targets multiple receptor tyrosine kinases (RTKs) involved in tumor growth and angiogenesis, including vascular endothelial growth factor receptors (VEGFRs), fibroblast growth factor receptors (FGFRs), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT. By inhibiting these kinases, denfivontinib aims to block signaling pathways that promote tumor cell proliferation and new blood vessel formation within tumors. The drug is being investigated primarily for use in advanced or metastatic cancers.
- Other names
- SKI-G-801SKI-G801SKI-G 801G-801G801G 801G-749 HClG749 HClG 749 HCl
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on denfivontinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on denfivontinib.